According to the research report titled ‘Antidepressant Drugs Market Size By Drug Class (Selective Serotonin Reuptake Inhibitors {SSRIs}, Serotonin-norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants), By Application (Major Depressive Disorder, Obsessive-compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027’, available with MarketStudyReport, global antidepressant drugs market is anticipated to showcase lucrative growth trends between 2021 and 2027.
 

Increasing prevalence of mental health disorders due to the COVID-19 outbreak coupled with rising product cognizance are few of the factors driving global antidepressant drugs market growth. Industry behemoths have been focusing on expanding the application scope of antidepressants, thereby adding traction to the overall market size. 
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4357548/
 

The COVID-19 pandemic, and the accompanying economic recession, has had a negative impact on public mental health, further posing new challenges for people already suffering from mental illnesses. According to a November 2020 study, 18% of individuals who tested positive for the COVID-19 virus (including both people with and without a previous psychiatric diagnosis) were later diagnosed with mental health illnesses such as mood disorders and anxiety.

Elderly people were also found to be more susceptible to a severe sickness caused by the Coronavirus as well as having higher levels of despair and anxiety. During the pandemic alone, these variables were critical in increasing product adoption, which in turn is adding traction to global antidepressants market size.
 

Furthermore, rising concerns related to the COVID-19 virus as well as limited social connections, have resulted in a global increase in depression and hence bolstering market remuneration off late.
 

Based on drug class, global antidepressant drugs market is segmented into serotonin & noradrenaline reuptake inhibitors (SNRIs), tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), and others. Among these, selective serotonin reuptake inhibitors segment is anticipated to showcase lucrative growth trends over the projected timespan, owing to rising prescription trend, increasing adoption, and significant costs of the product.
 

Considering the application range, the industry space is categorized into obsessive-compulsive disorder, panic disorder, major depressive disorder, generalized anxiety disorder, and others. As cited in the report, worldwide antidepressants industry share from major depressive disorder segment is slated to amass significant gains over the estimated timeline, on account of increasing prevalence of depression, along with negative impacts of the COVID-19 pandemic on mental health.
 

On the geographical front, the industry is categorized into North America, Asia Pacific, Latin America, Middle East & Africa, and Europe. Experts cite that North America is slated to grow significantly through 2027, owing to increasing prevalence of mental health issues, rising consumer awareness, and growing spending capacity of people in the region.
 

Major players profiled in worldwide antidepressant drugs industry space are OPKO Health Inc., Novartis International AG, Janssen Pharmaceuticals (Johnson & Johnson), Otsuka Pharmaceutical Co. Ltd., Intra-Cellular Therapies Inc., Sun Pharmaceutical Industries Ltd., Zhejiang NHU Co. Ltd., Takeda Pharmaceutical Company Limited, N.V. Organon, Sandoz Inc., Patheon Inc., GlaxoSmithKline plc, Bristol Myers Squibb, Pfizer Inc., and Eli Lilly and Company.